The BioFire Respiratory 2.

1 plus Panel
The BioFire Respiratory 2.1 plus ®

(RP2.1plus) Panel
1 Test. 23 Pathogens. 45 Minutes.

BioFire RP2.1plus Panel Targets

VIRUSES
Adenovirus Influenza A BACTERIA
Coronavirus 229E Influenza A/H1 Bordetella pertussis
Coronavirus HKU1 Influenza A/H3 Bordetella parapertussis
Coronavirus NL63 Influenza A/H1-2009 Chlamydia pneumoniae
Coronavirus OC43 Influenza B Mycoplasma pneumoniae
Middle East Respiratory Syndrome Parainfluenza Virus 1
Coronavirus (MERS-CoV) Parainfluenza Virus 2
Severe Acute Respiratory Syndrome Parainfluenza Virus 3
Coronavirus 2 (SARS-CoV-2) Parainfluenza Virus 4
Human Metapneumovirus Respiratory Syncytial Virus
Human Rhinovirus/Enterovirus

Is it COVID-19? The Flu? Or Something Else?

Identifying respiratory bugs has never been more urgent. 2018 to 2019 Respiratory Pathogen Trends1
But several respiratory bugs can cause similar, overlapping
symptoms. Data from BioFire® Syndromic Trends
demonstrate that even during peak “flu season”, influenza
comprised less than one third of detected respiratory
pathogens during this period. A comprehensive panel means
fewer missed detections.
 Knowing the Pathogen Matters
The BioFire® Respiratory 2.1 plus Panel

Reduce Reduce Hospital Costs Inform Clinical Decisions

Unnecessary Testing Adult ICU patients with a positive BioFire The hospital length of stay was nearly
Use of the BioFire RP Panel was shown RP Panel result saw a reduction in overall 5 days less for febrile infants with a positive
to reduce chest radiographs healthcare costs of $9,109 per patient BioFire RP Panel result compared to those
in children by 19%.2 compared to batch methods.3 with a negative result.4

Help Guide Antimicrobial Stewardship Programs

The US CDC estimates that 50% of outpatient prescriptions for
acute respiratory conditions are unnecessary, contributing to
increased levels of antibiotic resistance.5 Use of the BioFire® The BioFire RP Panel
FilmArray® Respiratory (RP) Panel has been shown to reduce
resulted in avoidance
of antibiotics in 30% of
antibiotic use by identifying respiratory viruses in a clinically
pediatric patients tested.6
actionable timeframe.6

Panel Specifications
Sample Type: Nasopharyngeal swab in transport media Hands-on Time: Approximately 2 minutes
Sample Volume: 300 μL Performance: 97.4% sensitivity and 99.4% specificity7
Storage Conditions: All kit components stored at room temperature (15–25 ˚C)

Part Numbers
BioFire RP2.1plus Panel Reagent Kit (30 Pouches): 423740

References
1. www.syndromictrends.com
2. Subramony A, et al. J Pediatr. 2016 Jun;173:196-201.e2.
3. Martinez R, et al. Geisinger Health System, CVS Poster, May 2016.
4. McFall, et al., Pediatrics. 2017 Feb;:000992281774066.
5. CDC. Antibiotic Use in the United States, 2017: Progress and Opportunities. Atlanta, GA: US Department of Health and Human Services, CDC; 2017.
6. S utton C, et al., ID Week 2017, poster 1607.
7. The stated performance is the aggregate of the prospective data from the clinical study.

Contact Us
bioMérieux S.A. Manufactured by:
BFR0000-3720-02

69280 Marcy l’Etoile France BioFire Diagnostics, LLC

Tel.: +33 (0) 4 78 87 20 00 515 Colorow Drive
Fax: +33 (0) 4 78 87 20 90 Salt Lake City, UT 84108
USA CE-marked US FDA-cleared
wwww.biomerieux.com www.biofiredx.com Product availability varies by country. Consult your bioMérieux representative.